ReviewMolecular cancer therapeutics2008
Dithiolethiones for cancer chemoprevention: where do we stand?
Review in Molecular cancer therapeutics, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 110 citations in OpenAlex.
- NOS2 and COX-2 Co-Expression Promotes Cancer Progression: A Potential Target for Developing Agents to Prevent or Treat Highly Aggressive Breast Cancer.International journal of molecular sciences · 2024Review
- ADT-OH improves intestinal barrier function and remodels the gut microbiota in DSS-induced colitis.Frontiers of medicine · 2023Article
- Dithiolethiones D3T and ACDT Protect Against Iron Overload-Induced Cytotoxicity and Serve as Ferroptosis Inhibitors in U-87 MG Cells.Neurochemical research · 2023Article
- How to Increase Cellular Glutathione.Antioxidants (Basel, Switzerland) · 2023Review
- Article
- HBiomolecules · 2021Review
- The age-dependent decline of the extracellular thiol-disulfide balance and its role in SARS-CoV-2 infection.Redox biology · 2021Article
- Discovery of 4-Anilinoquinolinylchalcone Derivatives as Potential NRF2 Activators.Molecules (Basel, Switzerland) · 2020Article
- Switchable Copper-Catalyzed Approach to Benzodithiole, Benzothiaselenole, and Dibenzodithiocine Skeletons.Organic letters · 2020Article
- Anethole Dithiolethione Increases Glutathione in Kidney by InhibitingOxidative medicine and cellular longevity · 2020Article
- Slow-Release HFrontiers in pharmacology · 2020Article
- Disubstituted Dithiolethione ACDT Exerts Neuroprotective Effects Against 6-Hydroxydopamine-Induced Oxidative Stress in SH-SY5Y Cells.Neurochemical research · 2019Article
- Ferritin in Kidney and Vascular Related Diseases: Novel Roles for an Old Player.Pharmaceuticals (Basel, Switzerland) · 2019Review
- Potential Role of H-Ferritin in Mitigating Valvular Mineralization.Arteriosclerosis, thrombosis, and vascular biology · 2019Article
- Sulforaphane: Its "Coming of Age" as a Clinically Relevant Nutraceutical in the Prevention and Treatment of Chronic Disease.Oxidative medicine and cellular longevity · 2019Review
- The new HJournal of enzyme inhibition and medicinal chemistry · 2018Article
- BET-ting on Nrf2: How Nrf2 Signaling can Influence the Therapeutic Activities of BET Protein Inhibitors.BioEssays : news and reviews in molecular, cellular and developmental biology · 2018Review
- Identification of Non-Electrophilic Nrf2 Activators from Approved Drugs.Molecules (Basel, Switzerland) · 2017Article
- The Nrf2/Keap1/ARE Pathway and Oxidative Stress as a Therapeutic Target in Type II Diabetes Mellitus.Journal of diabetes research · 2017Review
- 3H-1,2-dithiole-3-thione protects retinal pigment epithelium cells against Ultra-violet radiation via activation of Akt-mTORC1-dependent Nrf2-HO-1 signaling.Scientific reports · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
Abstract
Dithiolethiones are a well-known class of cancer chemopreventive agents; the key mechanism of action of dithiolethiones involves activation of Nrf2 signaling and induction of phase II enzymes. In the past, attention has been focused mainly on 4-methyl-5-pyrazinyl-3H-1,2-dithiole-3-thione (oltipraz), which showed ability as a wide-spectrum inhibitor of chemical carcinogenesis in preclinical models. However, clinical trials of oltipraz have shown questionable efficacy, and at the high doses employed in such studies, significant side effects were observed. Dithiolethiones that are markedly more effective and potent than oltipraz in both induction of phase II enzymes and inhibition of chemical carcinogenesis in preclinical studies have been identified, and these compounds have shown pronounced organ specificity in vivo. Further investigation of these compounds may lead to development of effective and safe agents for cancer prevention in humans.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.